Table 3.
Infants with congenital diaphragmatic hernia in the Neonatal Research Network
| 2011 | 2012 | Average | Range among centers | |
|---|---|---|---|---|
| Total CDH admissions | 175 | 162 | 169 | |
| CDH ≥ 36 0/7 week PMA | 142 | 133 | 138 (81%) | |
| Inhaled NO in the preoperative period among CDH ≥ 36 0/7 weeks PMA | 53 | 55 | 54 (39%) | 0–100% |
| Other medications used in the preoperative period among CDH ≥ 36 0/7 weeks PMA | ||||
| Milrinone | 17 | 29 | 23 (17%) | 0–70% |
| Sildenafil | 27 | 21 | 24 (17%) | 0–73% |
| Flolan ® (inhaled epoprostenol) | 8 | 9 | 9 (6%) | 0–68% a |
| Flolan ® (intravenous epoprostenol) | 6 | 3 | 5 (3%) | 0–25% a |
| Alprostadil (intravenous PGE1) | 6 | 5 | 6 (4%) | 0–50% |
| Epinephrine | 2 | 0 | 1 (1%) | 0–25% a |
| ECMO among all CDH | 59 | 56 | 58 (34%) | 8–87% |
| ECMO among CDH ≥ 36 0/7 weeks PMA | 51 | 48 | 50 (36%) | 9–59% |
| Survival to discharge | ||||
| - All CDH | 111 | 117 | 114 (68%) | 40–100% |
| - CDH ≥ 36 0/7 weeks PMA | 94 | 101 | 98 (71%) | 53–100% |
| Concern regarding use of iNO in CDH | Yes – 8; No – 11b | |||
| Primary physician managing pulmonary vasodilator therapy Surgeons – 4; Neonatologists – 10; Joint (surgeons + neonatologists – 3); Pediatric Intensivists – 1 |
||||
a These medications were used in one center only within the Network
b One center with two hospitals had a different response at each hospital